KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Receivables (2016 - 2025)

Amgen has reported Receivables over the past 17 years, most recently at $9.6 billion for Q4 2025.

  • Quarterly results put Receivables at $9.6 billion for Q4 2025, up 31.04% from a year ago — trailing twelve months through Dec 2025 was $9.6 billion (up 31.04% YoY), and the annual figure for FY2025 was $9.6 billion, up 31.04%.
  • Receivables for Q4 2025 was $9.6 billion at Amgen, up from $8.5 billion in the prior quarter.
  • Over the last five years, Receivables for AMGN hit a ceiling of $9.6 billion in Q4 2025 and a floor of $4.4 billion in Q1 2021.
  • Median Receivables over the past 5 years was $6.2 billion (2022), compared with a mean of $6.5 billion.
  • Biggest five-year swings in Receivables: dropped 16.53% in 2021 and later surged 31.04% in 2025.
  • Amgen's Receivables stood at $4.9 billion in 2021, then rose by 27.4% to $6.3 billion in 2022, then increased by 24.06% to $7.8 billion in 2023, then fell by 6.01% to $7.3 billion in 2024, then surged by 31.04% to $9.6 billion in 2025.
  • The last three reported values for Receivables were $9.6 billion (Q4 2025), $8.5 billion (Q3 2025), and $8.7 billion (Q2 2025) per Business Quant data.